Analyst Rating Update on TherapeuticsMD (TXMD)

TherapeuticsMD (NYSEMKT:TXMD) : 4 brokerage houses believe that TherapeuticsMD (NYSEMKT:TXMD) is a Strong Buy at current levels. Zacks Investment Research suggests a Hold with a rank of 3.The median of all the 4 Wall Street Analysts endorse the stock as a Strong Buy with a rating of 1.

TherapeuticsMD (NYSEMKT:TXMD) has been rated by 4 research analysts. Fundamentally, the highest shorterm price forecast for the stock is expected to reach $18 and the lowest price target forecast is $13. The average forecast of all the analysts is $15.63 and the expected standard deviation is $2.5.

For the current week, the company shares have a recommendation consensus of Buy. Also, Goldman Sachs initiates coverage on TherapeuticsMD (NYSEMKT:TXMD). Goldman Sachs has a Buy rating on the shares. As per the latest report, the brokerage house announces the price target to $10 per share. The rating by the firm was issued on April 4, 2016.

TherapeuticsMD (NYSEMKT:TXMD): stock turned positive on Tuesday. Though the stock opened at $8.38, the bulls momentum made the stock top out at $8.73 level for the day. The stock recorded a low of $8.33 and closed the trading day at $8.61, in the green by 4.49%. The total traded volume for the day was 1,367,035. The stock had closed at $8.24 in the previous days trading.

In an insider trading activity, Collins Cooper C., director of Therapeuticsmd, Inc. had purchased 16,000 shares on March 11, 2016 in a transaction. The price per share was $6.23 and the total amount of the disclosed transaction was $99,680.The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing. This information is based on open market transaction at the market prices.

TherapeuticsMD, Inc. is a womens health care product company. The Company is engaged in creating and commercializing products for women. The Company is focused on conducting clinical trials necessary for regulatory approval and commercialization of advanced hormone therapy pharmaceutical products. It manufactures and distributes branded and generic prescription prenatal vitamins, as well as over-the-counter (OTC) vitamins. It markets its prescription and OTC prenatal vitamins and other products under its vitaMedMD brand name and duplicate formulations of its prescription prenatal vitamin products, also referred to as generic formulations, under its BocaGreenMD brand name. The Companys products include prenatal vitamins, vitaMedMD Plus Rx, vitaMedMD One Rx, vitaMedMD RediChew Rx and BocaGreenMD Prena1 line of prescription prenatal vitamins, which included three prescription prenatal vitamins that were generic formulations of its vitaMedMD-branded prescription prenatal vitamins.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.